125/25 mcg once-daily GSK573719/GW642444; 125mcg once-daily GSK573719; Placebo once-daily
Проводит ГлаксоСмитКляйн ЛЛС
Страница компанииA 52 Week Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 125mcg Once-daily Alone and in Combination With GW642444 25mcg Once-daily Via Novel Dry Powder Inhaler (nDPI) in Subjects With Chronic Obstructive Pulmonary Disease
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT01316887/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 40–120 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 563 чел. во всех странах исследования.
- Плановая дата окончания (07.2012) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 7 · невключение: 39
Критерии включения
- outpatient
- signed and dated written informed consent
- 40 years of age or older
- male and female subjects
- COPD diagnosis
- at least 10 pack-year smoking history
- post-albuterol/salbutamol FEV1/FVC ratio of <0.70 and post-albuterol/salbutamol FEV1 greater than or equal to 35% and less than or equal to 80% of predicted normal
Критерии невключения
- Pregant or lactating women or women planning to become pregnant during the study
- current diagnosis of asthma
- other respiratory disorders other than COPD
- other diseases/abnormalities that are uncontrolled including cancer not in remission for at least 5 years
- chest x-ray or CT scan with clinically significant abnormalities not believed to be due to COPD
- hypersensitivity to anticholinergics, beta-agonists, lactose/milk protein or magnesium stearate or medical conditions associated with inhaled anticholinergics
- hospitalization for COPD or pneumonia within 12 weeks prior to Visit 1
- lung volume reduction surgery within 12 months prior to Visit 1
- abnormal and clinically significant ECG at Visit 1
- abnormal and clinically significant Holter monitor finding at Visit 1
- significantly abnormal finding from laboratory tests at Visit 1
- unable to withhold albuterol/salbutamol and/or ipratropium bromide at least 4 hours prior to spirometry at each visit
- use of depot corticosteroids within 12 weeks of Visit 1
- use of oral or parenteral corticosteroids within 6 weeks of Visit 1
- use of anitbiotics for lower respiratory tract infection within 6 weeks of Visit 1
- use of cytochrome P450 3A4 inhibitors within 6 weeks of Visit 1
- us of long-acting beta-agonist (LABA)/inhaled corticosteroid (ICS) products if LABA/ICS therapy is discontinued completely within 30 days of Visit 1
- use of ICS at a dose of >10000mcg/day of fluticasone propionate or equivalent within 30 days of Visit 1
- initiation or discontinuation of ICS within 30 days of Visit 1
- use of tiotropium within 14 days of Visit 1
- use of roflumilast within 14 days of Visit 1
- use of theophyllines within 48 hours of Visit 1
- use of oral leukotriene inhibitors within 48 hours prior to Visit 1
- use of long-acting oral beta-agonists within 48 hours of Visit 1
- use of short-acting oral beta-agonists within 12 hours of Visit 1
- use of inhaled long-acting beta-agonists within 48 hours prior to Visit 1
- use of LABA/ICS combination products only if discontinuing LABA therapy and switching to ICS monotherapy within 48 hours of Visit 1 for the LABA component
- use of sodium cromoglycate or nedocromil sodium within 24 hours of Visit 1
- use of inhaled short acting beta-agonists within 4 hours of Visit 1
- use of inhaled short-acting anticholinergics within 4 hours of Visit 1
- use of inhaled short-acting anticholinergic/short-acting beta2-agonist combination products within 4 hours of Visit 1
- use of any other investigational medication within 30 days or 5 drug half-lives (whichever is longer) of Visit 1
- long-term oxygen therapy prescribed for >12 hours per day
- regular use of short-acting bronchodilators
- use of CPAP or NIPPV
- participation in the maintenance phase of a pulmonary rehabilitation program
- known or suspected history of alcohol or drug abluse with 2 years prior to Visit 1
- anyone affiliated with the investigator site (e.g., investigator, study coordinator, etc.)
- previous use of GSK573719, GW642444 , GSK573719/GW642444 combination, GSK233705/GW642444 combination, or Fluticasone Furoate/GW642444 combination
Источник: ClinicalTrials.gov, NCT01316887 · запись обновлена в реестре 2 мая 2018.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 18
- Number of Participants With Any On-treatment Adverse Event (AE) or Any Serious Adverse Event (SAE) — From the start of study drug up to 52 weeks
Цель исследования
The purpose of this 52-week study is to evaluate the long-term safety (in terms of adverse events, COPD exacerbations, laboratory, ECG, and Holter findings, vital signs, use of rescue medication and lung function) of GSK573719/GW642444 Inhalation Powder 125/25mcg in subjects with COPD. The long-term safety of GSK573719 Inhalation Powder 125mcg will also be evaluated. A placebo arm is included to evaluate these products compared to an inactive control.
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT01316887 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.